Cerebrolysin
Also known as: FPF-1070
A peptide preparation from pig brain with neurotrophic effects.
Overview
Cerebrolysin is a peptide preparation derived from porcine brain tissue, containing low molecular weight peptides and amino acids with neurotrophic activity. Used globally for stroke and dementia.
Mechanism of Action
Contains multiple neurotrophic factors that mimic endogenous growth factors. Promotes neuroplasticity, reduces amyloid aggregation, and has anti-inflammatory effects on neurons.
Pharmacokinetics
IV or IM administration. Peptides cross BBB due to small size. Duration of effects extends beyond treatment period.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Acute Stroke
30-50 ml
Once daily IV
10-21 days
Diluted in saline
Cognitive Support
10-30 ml
Daily IV/IM
4 weeks
May repeat courses
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Approved in many countries for stroke and dementia
- 2Meta-analyses support efficacy in acute stroke
- 3Improved cognitive function in Alzheimer's trials
- 4Neuroprotective in TBI models
Side Effects & Contraindications
Reported Side Effects
- Dizziness
- Agitation
- Injection site reactions
Contraindications
- Epilepsy (relative)
- Severe renal failure
- Allergic to porcine proteins
Safety Considerations
Generally well-tolerated. Derived from animal tissue. Injection site reactions possible.
Storage Requirements
Store at 2-8C. Protect from light.
Scientific References
- 1